Olive Oil Boosts Heart Health
FDA Announces: Olive Oil May Boost Heart Health November 8, 2004 Food containing olive oil can carry labels saying they may reduce the risk of coronary heart disease, the government says, citing limited evidence from a dozen scientific studies about the benefits of monounsaturated fats.
As long as people don’t increase the number of calories they consume daily, the Food and Drug Administration confirmed a reduction in the risk of coronary heart disease when people replace foods high in saturated fat with the monounsaturated fat in olive oil.
That means a change as simple as sauteing food in two tablespoons of olive oil instead of butter may be healthier for your heart.
“”Since CHD is the No. 1 killer of both men and women in the United States, it is a public health priority to make sure that consumers have accurate and useful information on reducing their risk,”" Lester M. Crawford, acting FDA commissioner, said in a prepared statement.
“”It’s good news for consumers,”" said Bob Bauer, president of the North American Olive Oil Association, which sought the qualified health claim on Aug. 28, 2003. “”Olive oil is a healthy product to help them fight heart disease.”"
Recent research has underscored the heart benefits from so-called Mediterranean diets high in unsaturated fats from vegetable oil, nuts and such fish as salmon and tuna. Mortality rates dropped by more than 50 percent among elderly Europeans who stuck to such diets and led healthy lifestyles, according to research published in the Journal of the American Medical Association in September.
The North American Olive Oil Association included 88 publications to back its claim for the heart-healthy benefits of olive oil. The group wanted to make the claim for monounsaturated fats contained in just one tablespoon of olive oil per day.
Olive oil and certain food containing olive oil can now indicate that “”limited and not conclusive scientific evidence suggests that eating about two tablespoons (23 grams) of olive oil daily may reduce the risk of coronary heart disease due to the monounsaturated fat in olive oil,”" the FDA concluded.
“”I think FDA just took a more conservative view,”" Bauer said. Manufacturers waited for the FDA’s precise wording before revising labels. “”I expect, over time, most every container of olive oil will have this,”" he said.
Already, American restaurants and consumers drive $450 million in olive oil sales per year. Supermarket sales in 2003 accounted for 132 million pounds of olive oil, up by nearly one-third over the past six years. Bauer said he expects the label change to spur a larger uptick in sales.
According to the American Heart Association, coronary heart disease caused 502,189 deaths — or one in five deaths — in 2001, the most current statistic available. Another 13.2 million Americans that year survived the heart attacks, chest pains and other ailments caused by coronary heart disease.
Along with lowering cholesterol, cutting out cigarettes and exercising, the group says Americans can boost heart health by eating foods low in saturated fat, cholesterol and sodium. An American Heart Association spokeswoman declined comment on the FDA’s action until it reviews the health claim.
The FDA discounted most of the submitted studies because the methodology made it difficult to tease out the effect of the monounsaturated fats in olive oil. Of a dozen studies that survived the cut, four were the most persuasive.
Thirty-three healthy young American men ate diets high in saturated fats from butter or cocoa butter, olive oil’s monounsaturated fats or polyunsaturated fats from soybean oil. The soybean and olive oil groups significantly lowered total and bad LDL cholesterol.
In another trial involving 21 middle-aged Spanish women, those with diets in which olive oil replaced 8 percent of total daily calories from saturated fats lowered their total and bad cholesterol while significantly boosting good HDL cholesterol.
Forty-one young Spanish men lowered total and bad LDL cholesterol with an olive oil diet. Levels of good cholesterol did not drop in the olive oil group, as they did for youthful peers who replaced calories from saturated fats with carbohydrates.
And 22 healthy, middle-aged Spanish men with slightly elevated cholesterol counts were put on a four-week diet high in saturated fat. Those who switched to diets high in olive oil and those who replaced calories from saturated fats with carbohydrates lowered total and bad LDL cholesterol levels.
It’s the third time the FDA granted a qualified health claim for conventional food. In March, the agency said “”supportive but not conclusive research”" shows eating 1.5 ounces of walnuts per day may reduce coronary heart disease risk. In September, it issued a similar qualified claim for the heart-healthy benefits of omega-3 fatty acids.
The FDA press release: http://www.fda.gov/bbs/topics/news/2004/NEW01129.html
Pine Bark Extract Boosts Heart Health
Pine Bark Extract Boost Diabetics’ Heart Health May 13, 2008
Supplements of extracts from French maritime pine bark reduce blood pressure and the use of blood pressure medication among diabetics, concludes results from a new study.
Blood pressure control was achieved in 58 per cent of study participants, and a halving of the use of medication, among 48 participants randomly assigned to daily supplements of pine bark extract or placebo for 12 weeks. The results of the new study, published in the May issue of the journal Nutrition Research, is of particular importance for diabetics who are reportedly two to four times more likely to suffer from heart disease than non-diabetics “”These data confirm the hypothesis that pine bark extract improves diabetes control, reduces antihypertensive medicine use, and may favour a reduction in cardiovascular disease risk in individuals with type 2 diabetes,”" wrote lead author Sherma Zibadi from the University of Arizona. Indeed, previous studies have reported potential health benefits for the extract, including hypertension, asthma, chronic venous insufficiency, osteoarthritis, deep vein thrombosis, diabetes management, and diabetic leg ulcers. The new study recruited diabetic subjects with an average age of 60 and randomly assigned them to receive daily supplements of pine bark extract (125 mg) or placebo for 12 weeks in a randomized, double-blind, placebo-controlled trial with parallel-group design. All subjects were receiving pharmaceutical anti-hypertension treatment (angiotensin- converting enzyme [ACE] inhibitors). At the end of the study, Zibadi and co-workers report that 58.3 per cent of subjects in the pine bark extract group experienced blood pressure control, defined as attaining a stable systolic blood pressure, compared to 20.8 per cent in the placebo group. Moreover, use of ACE inhibitors was reduced by 50 per cent in the group receiving the pine bark extract Improvements in measures of diabetes control were also recorded, with a 23.7 mg/dL reduction in fasting blood glucose levels in the pine bark extract group, compared to only 5.7 mg/dL in the placebo group. Improvements in LDL-cholesterol, a marker of cardiovascular health, were recorded in the pine bark extract-supplemented group. After eight and 12 weeks of supplementation, decreases of 11.6 and 12.7 mg/dL were observed, respectively, compared with placebo. Mechanism of Action In attempting to understand the benefits of the pine bark extract on cardiovascular health of the diabetics, the researchers noted that the blood pressure lowering effects may be due to a suppression of serum endothelin-1, a protein that restricts blood vessels and reported to be found in higher levels than normal in type 2 diabetics and hypertensives. On the other hand, the authors could not rule out the potential of an inhibitory effect on ACE, which could improve blood flow and subsequently blood pressure. Finally, other studies have reported a potential benefit from pine bark extract on the production of the potent vasodilator, nitric oxide (NO). Limitations About 26.5 million people are affected by diabetes in the European Union, United States, and Canada equal to four per cent of the total population. This figure is projected to increase to 40 million by 2030. In the US, there are over 20 million people with diabetes, equal to seven per cent of the population. The total costs are thought to be as much as $132 billion, with $92 billion being direct costs from medication, according to 2002 American Diabetes Association figures.
Source: Nutrition Research (Elsevier) May 2008, Volume 28, Issue 5, Pages 315-320 “”Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation”" Authors: S. Zibadi, P.J. Rohdewald, D. Park, R.R. Watson